Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer.
- Author:
Jie LI
1
;
Ming LU
;
Lin SHEN
;
Xiao-Dong ZHANG
;
Yan LI
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Esophagogastric Junction; Female; Fluorouracil; adverse effects; therapeutic use; Follow-Up Studies; Humans; Leucovorin; adverse effects; therapeutic use; Leukopenia; chemically induced; Male; Middle Aged; Nausea; chemically induced; Neoplasm Staging; Neutropenia; chemically induced; Organoplatinum Compounds; administration & dosage; adverse effects; therapeutic use; Remission Induction; Retrospective Studies; Stomach Neoplasms; drug therapy; pathology; Survival Rate; Thrombocytopenia; chemically induced; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2009;31(12):933-936
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of oxaliplatin-based regimen in patients with advanced or metastatic gastric/esophagogastric junction cancer (AGC).
METHODSThe clinicopathological data of a total of 180 patients with AGC were retrospectively analyzed. Responses was evaluated by RECIST criteria, and toxicity were assessed according to the NCI-CTC AE version 3.0.
RESULTS155 patients received mFOLFOX regimen, and 25 patients received regimens of mEOF and CapOX, with a total chemotherapy of 717 cycles with a median of 3 cycles. The therapeutic response was evaluated in 150 patients, showing response rate (RR) of 30.0% and disease control rate (DCR) of 74.0%. The response was evaluated in 103 of 124 patients who received the therapy as 1st line, with RR of 34.0%, DCR of 74.8%, and overall survival of 11.3 months. The major grade III/IV adverse events were leucocytopenia (14.4%), neutropenia (17.8%), thrombocytopenia (3.8%), nausea/vomiting (8.9%), and peripheral neuropathy (2.2%), with no treatment related death.
CONCLUSIONOxaliplatin-based regimen is active and well tolerated in patients with advanced or metastatic gastric/esophagogastric junction cancer.
